Cytokine polymorphisms and genotypic susceptibility of HCV infection in ribavirin response to peg interferon

被引:1
|
作者
Mohammad, Y. A. [1 ]
Mohammed, A. [1 ]
Muath, S. [1 ]
机构
[1] King Khalid Univ, Coll Appl Med Sci, Dept Clin Lab Sci, Abha 61413, Saudi Arabia
关键词
HCV genotypes; cytokines; polymorphisms; ribavirin; peg interferon; HEPATITIS-C VIRUS; IL28B POLYMORPHISM; GENE POLYMORPHISM; EPIDEMIOLOGY; ASSOCIATION; FIBROSIS; THERAPY; IMPACT; IL-10; RISK;
D O I
10.47665/tb.40.3.009
中图分类号
R38 [医学寄生虫学]; Q [生物科学];
学科分类号
07 ; 0710 ; 09 ; 100103 ;
摘要
Immune responses are largely regulated by cytokines. Genetic polymorphisms of the regulatory coding regions are recognized to impact the expression of cytokines. The abnormal cytokine levels in hepatitis C virus (HCV) infection seems to be involved in disease progression, viral survival, and therapeutic response. The current study assesses the polymorphisms associated with IL-6, IL-10, IL28B, IFN-gamma, TGF-beta, and TNF-alpha on the genotypic susceptibility to HCV infection and Ribavirin response to Peg interferon. Droplet digital polymerase chain reaction (PCR) was used to assess the gene polymorphisms associated with IL-6 A/G (rs2069837), IL-10-1082 G/A (rs1800896)], IL28B C/T (rs12979860), IFN-gamma +874 A/T (rs2430561), TGF-beta 1-509 C/T (rs1800469) and TNF-alpha-308 G/A promoter (rs1800629) from stored samples of 200 healthy individuals and 300 HCV infected patients. There was a significant association of AG and AA genotypes of IL28B, IFN-gamma, TGF-beta 1, and TNF-alpha over HCV susceptibility and treatment outcome. However, no association between IL-6 and IL-10 gene polymorphism to HCV susceptibility response to the treatment. The observations indicate IL28B CT, TGF-beta 1 CT, TT and TNF- AG with AA genotypes influence the cytokine expression, which is related to susceptibility and resistance to HCV infection and combined antiviral therapy.
引用
收藏
页码:331 / 336
页数:6
相关论文
共 50 条
  • [41] Genetic contribution of suppressor of cytokine signalling polymorphisms to the susceptibility to infection after traumatic injury
    Zhang, A.
    Gu, W.
    Lu, H.
    Zeng, L.
    Zhang, L.
    Du, D.
    Hao, J.
    Wen, D.
    Wang, X.
    Jiang, J.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2018, 194 (01) : 93 - 102
  • [42] Consensus interferon versus interferon-α 2b plus ribavirin in patients with relapsing HCV infection
    Miglioresi, L
    Bacosi, M
    Russo, F
    Patrizi, F
    Saccenti, P
    Ursitti, A
    De Angelis, A
    Ricci, GL
    HEPATOLOGY RESEARCH, 2003, 27 (04) : 253 - 259
  • [43] HLA-G regulatory polymorphisms are associated with susceptibility to HCV infection
    Catamo, E.
    Zupin, L.
    Freato, N.
    Polesello, V.
    Celsi, F.
    Croce, S. L.
    Masutti, F.
    Pozzato, G.
    Segat, L.
    Crovella, S.
    HLA, 2017, 89 (03) : 135 - 142
  • [44] Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load
    Neukam, Karin
    Camacho, Angela
    Caruz, Antonio
    Rallon, Norma
    Torres-Cornejo, Almudena
    Rockstroh, Juergen K.
    Macias, Juan
    Rivero, Antonio
    Benito, Jose M.
    Lopez-Cortes, Luis F.
    Nattermann, Jacob
    Gomez-Mateos, Jesus
    Soriano, Vicente
    Pineda, Juan A.
    JOURNAL OF HEPATOLOGY, 2012, 56 (04) : 788 - 794
  • [45] CD40 polymorphisms were associated with HCV infection susceptibility among Chinese population
    Tian, Ting
    Huang, Peng
    Wu, Jingjing
    Wang, Chunhui
    Fan, Haozhi
    Zhang, Yun
    Yu, Rongbin
    Wu, Chao
    Xia, Xueshan
    Fu, Zuqiang
    Li, Jun
    Yue, Ming
    BMC INFECTIOUS DISEASES, 2019, 19 (01)
  • [46] Ribavirin dosage in patients with HCV genotypes 2 and 3 who completed short therapy with peg-interferon α-2b and ribavirin
    Mangia, A.
    Dalgard, O.
    Minerva, N.
    Verbaan, H.
    Bacca, D.
    Ring-Larsen, H.
    Copetti, M.
    Carretta, V.
    Piazzolla, V.
    Cozzolongo, R.
    Mottola, L.
    Andriulli, A.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2010, 31 (12) : 1346 - 1353
  • [47] First Week HCV RNA Level Under the Pegylated Interferon and Ribavirin Treatment Predicts Sustained Virological Response
    Bayram, Mehmet
    Koksal, Ali Riza
    Alkim, Huseyin
    Boga, Salih
    Ergun, Meltem
    Ozdogan, Osman
    Altinkaya, Engin
    Alkim, Canan
    AMERICAN JOURNAL OF THERAPEUTICS, 2016, 23 (06) : E1612 - E1618
  • [48] Predictive Factors for Response to Peginterferon-Alpha and Ribavirin Treatment of Chronic HCV Infection in Patients Aged 65 Years and More
    Giannini, Edoardo G.
    Basso, Monica
    Savarino, Vincenzo
    Picciotto, Antonino
    DIGESTIVE DISEASES AND SCIENCES, 2010, 55 (11) : 3193 - 3199
  • [49] Evaluation of Interleukin-8 in Hepatitis C Virus Infection: Relation to Combined peg-interferon Ribavirin Response and Genotype 4
    El Sayed, Zaki Maysaa
    Mansour, F. A.
    Ghal, M. F.
    Abou-Zahra, S. B.
    IMMUNOLOGICAL INVESTIGATIONS, 2011, 40 (01) : 29 - 38
  • [50] HCV-specific CD8+ cell detection at week 12 of chronic hepatitis C treatment with PEG-interferon-α2b/ribavirin correlates with infection resolution
    Larrubia, Juan-Ramon
    Lokhande, Megha-Uttam
    Moreno-Cubero, Elia
    Garcia-Garzon, Silvia
    Miguel, Joaquin
    Parra-Cid, Trinidad
    Gonzalez-Praetorious, Alejandro
    Perna, Cristian
    Lazaro, Alicia
    Sanz-de-Villalobos, Eduardo
    CELLULAR IMMUNOLOGY, 2013, 286 (1-2) : 31 - 38